Triticale, Still a Promise?

HSP90 inhibitors in lung cancer: promise still unfulfilled.

Despite recent advances in the treatment of lung cancer, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths in the United States and worldwide, with a 5-year survival rate of less than 17%. Analysis of the molecular drivers of NSCLC led to the recognition that NSCLC is a collection of distinct, molecularly driven neoplasms. Several subsets of NSCLC with clinic...

Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?

ucleic acid-based therapy holds the potential for a new era in the treatment of life-threatening disease. Advances in the use of antisense oligodeoxynucleotides (ODNs) as inhibitor of aberrant gene expression in neoplastic cells have been reviewed in a recent issue of this Journal; since new reports are continuously appearing, the present state of the art needs to be defined again. The optimism...

Registration of ‘NE422T’ Winter Triticale

Revisiting O1-antitrypsin therapy in cystic fibrosis: can it still offer promise?

T he contribution of the neutrophil-derived serine protease neutrophil elastase (NE) to lung disease in cystic fibrosis (CF) is unquestioned and yet, despite promising preliminary studies in the last 20 yrs to investigate an effective therapy to negate the damaging effect of NE [1], this treatment has failed to take off for patients with CF. This is largely due to the scarcity of clinical trial...

Experimental Analysis of a Vertical, Double-Effect Diffusion Solar Still